DBV Technologies S.A - Stock Price History | DBVT

Historical daily share price chart and data for DBV Technologies S.A since 2021 adjusted for splits. The latest closing stock price for DBV Technologies S.A as of October 22, 2021 is 5.52.
  • The all-time high DBV Technologies S.A stock closing price was 49.36 on October 11, 2017.
  • The DBV Technologies S.A 52-week high stock price is 7.38, which is 33.7% above the current share price.
  • The DBV Technologies S.A 52-week low stock price is 1.35, which is 75.5% below the current share price.
  • The average DBV Technologies S.A stock price for the last 52 weeks is 4.88.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
DBV Technologies S.A Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.7560 11.0200 12.9800 1.3800 2.6200 -75.51%
2019 8.5245 6.9900 11.1500 5.8100 10.7000 66.67%
2018 20.6314 25.4600 26.6000 5.7500 6.4200 -73.90%
2017 35.2508 34.7300 49.3600 20.9000 24.6000 -29.97%
2016 32.8193 35.4000 37.6700 23.0200 35.1300 -3.25%
2015 31.0632 28.2000 44.3700 20.6200 36.3100 33.89%
2014 25.7196 22.9000 28.5000 22.9000 27.1200 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.607B $0.011B
DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76